These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 15640610

  • 1. Effects of intravenous polymaltose iron on oxidant stress and non-transferrin-bound iron in hemodialysis patients.
    Driss F, Vrtovsnik F, Katsahian S, Michel C, Baron G, Kolta A, Sedrati N, Mentré F, Mignon F, Cabantchik I, Grandchamp B.
    Nephron Clin Pract; 2005; 99(3):c63-7. PubMed ID: 15640610
    [Abstract] [Full Text] [Related]

  • 2. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.
    Pai AB, Conner T, McQuade CR, Olp J, Hicks P.
    Biometals; 2011 Aug; 24(4):603-13. PubMed ID: 21229380
    [Abstract] [Full Text] [Related]

  • 3. Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron.
    Prakash M, Upadhya S, Prabhu R.
    Clin Chim Acta; 2005 Oct; 360(1-2):194-8. PubMed ID: 15979061
    [Abstract] [Full Text] [Related]

  • 4. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
    Malindretos P, Sarafidis PA, Rudenco I, Raptis V, Makedou K, Makedou A, Grekas DM.
    Am J Nephrol; 2007 Oct; 27(6):572-9. PubMed ID: 17804904
    [Abstract] [Full Text] [Related]

  • 5. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
    Cavdar C, Temiz A, Yeniçerioğlu Y, Calişkan S, Celik A, Sifil A, Onvural B, Camsari T.
    Scand J Urol Nephrol; 2003 Oct; 37(1):77-82. PubMed ID: 12745750
    [Abstract] [Full Text] [Related]

  • 6. The effect of serum albumin level on iron-induced oxidative stress in chronic renal failure patients.
    Sezer MT, Akin H, Demir M, Erturk J, Aydin ZD, Savik E, Tunc N.
    J Nephrol; 2007 Oct; 20(2):196-203. PubMed ID: 17514624
    [Abstract] [Full Text] [Related]

  • 7. Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.
    Conner TA, McQuade C, Olp J, Pai AB.
    Biometals; 2012 Oct; 25(5):961-9. PubMed ID: 22706571
    [Abstract] [Full Text] [Related]

  • 8. Ascorbyl free radical reflects catalytically active iron after intravenous iron saccharate injection.
    Stefánsson BV, Haraldsson B, Nilsson U.
    Free Radic Biol Med; 2008 Nov 01; 45(9):1302-7. PubMed ID: 18775775
    [Abstract] [Full Text] [Related]

  • 9. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation.
    Scheiber-Mojdehkar B, Lutzky B, Schaufler R, Sturm B, Goldenberg H.
    J Am Soc Nephrol; 2004 Jun 01; 15(6):1648-55. PubMed ID: 15153577
    [Abstract] [Full Text] [Related]

  • 10. Non-transferrin-bound iron is associated with enhanced Staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose.
    Barton Pai A, Pai MP, Depczynski J, McQuade CR, Mercier RC.
    Am J Nephrol; 2006 Jun 01; 26(3):304-9. PubMed ID: 16809897
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P, Banké-Bochita J.
    Arzneimittelforschung; 2010 Jun 01; 60(6a):362-72. PubMed ID: 20648928
    [Abstract] [Full Text] [Related]

  • 12. Minor impairment of oral iron absorption in non-diabetic new dialysis patients.
    Tovbin D, Schnaider A, Vorobiov M, Rogachev B, Basok A, Shull P, Novack V, Friger M, Avramov D, Zlotnik M.
    J Nephrol; 2005 Jun 01; 18(2):174-80. PubMed ID: 15931645
    [Abstract] [Full Text] [Related]

  • 13. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study.
    Anraku M, Kitamura K, Shintomo R, Takeuchi K, Ikeda H, Nagano J, Ko T, Mera K, Tomita K, Otagiri M.
    Clin Biochem; 2008 Oct 01; 41(14-15):1168-74. PubMed ID: 18692036
    [Abstract] [Full Text] [Related]

  • 14. Safety of intravenous injection of iron saccharate in haemodialysis patients.
    Sunder-Plassmann G, Hörl WH.
    Nephrol Dial Transplant; 1996 Sep 01; 11(9):1797-802. PubMed ID: 8918625
    [Abstract] [Full Text] [Related]

  • 15. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
    Gallucci MT, Lubrano R, Meloni C, Morosetti M, Manca di Villahermosa S, Scoppi P, Palombo G, Castello MA, Casciani CU.
    Clin Nephrol; 1999 Oct 01; 52(4):239-45. PubMed ID: 10543326
    [Abstract] [Full Text] [Related]

  • 16. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
    Maruyama Y, Nakayama M, Yoshimura K, Nakano H, Yamamoto H, Yokoyama K, Lindholm B.
    Nephrol Dial Transplant; 2007 May 01; 22(5):1407-12. PubMed ID: 17264097
    [Abstract] [Full Text] [Related]

  • 17. Does non-transferrin bound iron contribute to transfusion related immune-modulation in preterms?
    Stark MJ, Keir AK, Andersen CC.
    Arch Dis Child Fetal Neonatal Ed; 2013 Sep 01; 98(5):F424-9. PubMed ID: 23475935
    [Abstract] [Full Text] [Related]

  • 18. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
    Swarnalatha G, Ram R, Neela P, Naidu MU, Dakshina Murty KV.
    Saudi J Kidney Dis Transpl; 2010 Sep 01; 21(5):852-8. PubMed ID: 20814119
    [Abstract] [Full Text] [Related]

  • 19. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC, Hung SC, Tarng DC.
    Am J Kidney Dis; 2006 Jun 01; 47(6):1036-44. PubMed ID: 16731299
    [Abstract] [Full Text] [Related]

  • 20. Experience with the use of an iron polymaltose (dextrin) complex given by single total dose infusion to stable chronic haemodialysis patients.
    van Zyl-Smit R, Halkett JA.
    Nephron; 2002 Oct 01; 92(2):316-23. PubMed ID: 12218309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.